Gedatolisib Combo Approved for Advanced Breast Cancer

Published Date: 17 Jul 2026

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Read Full News

Latest News

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Sequencing Method Flags AML Relapse Risk Around Transplant

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Latest News

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

News All Time

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Recommended News For You

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

Gedatolisib Combo Approved for Advanced Breast Cancer

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.

AMA President-Elect Confronts a New Challenge: A Brain Tumor

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Recommended Articles For You

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care 

Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions 

Cancer Prevention Through Early Immune Surveillance Enhancement 

Demystifying Hematoma Rectus Sheath: Knowing the Symptoms and Causes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parkinson patient's gait is restored by a spinal cord stimulator.

2.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

3.

automated, precise reporting for clonality testing using NGS.

4.

Are Microplastics Feeding Cancer Risk?

5.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

1.

Understanding Protein C Deficiency: Symptoms, Causes, and Treatment

2.

Tumor Dormancy and Cancer Recurrence: Mechanisms, Clinical Implications, and Future Directions

3.

Immune Microenvironment Biomarkers for Early Tumor Evolution

4.

The Future of Oncology: Innovations Every Doctor Should Know

5.

What You Need to Know About the Early Warning Signs of Colon Cancer 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

5.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot